Samfara finalise l'acquisition de Chr. Olesen Synthesis, fabricant danois de principes actifs pharmaceutiques (API) soumis à un contrôle réglementaire

Summary

Samfara has completed its acquisition of Chr. Olesen Synthesis, a Danish pharmaceutical active pharmaceutical ingredient (API) manufacturer subject to regulatory oversight. The deal marks Samfara's first investment and is backed by a consortium of European and North American institutional investors and family offices.